Outcomes in COVID-19 darunavir studies

All studies   Mortality   Serious outcomes   Viral clearance   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -34% 5 2K Improvement, Studies, Patients Relative Risk Mortality -34% 4 2K Viral clearance -22% 1 30 RCTs -22% 1 30 Early -22% 1 30 Late -34% 4 2K Darunavir for COVID-19 c19early.org December 2025 Favorsdarunavir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Early treatment -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk Nicolini -32% 1.32 [0.85-2.06] death 151 (n) 177 (n) Improvement, RR [CI] Treatment Control Kim 87% 0.13 [0.02-0.68] death 2/14 14/28 Milic -150% 2.50 [1.58-3.94] death 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] death 479 (n) 1,824 (n) Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Late treatment -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk All studies -34% 1.34 [0.82-2.20] 2/774 14/2,202 34% higher risk 5 darunavir COVID-19 studies c19early.org December 2025 Tau​2​ = 0.22, I​2​ = 79.7%, p = 0.24 Effect extraction pre-specified(most serious outcome) Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Nicolini -32% 1.32 [0.85-2.06] 151 (n) 177 (n) Improvement, RR [CI] Treatment Control Kim 87% 0.13 [0.02-0.68] 2/14 14/28 Milic -150% 2.50 [1.58-3.94] 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] 479 (n) 1,824 (n) Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Late treatment -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk All studies -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk 4 darunavir COVID-19 mortality results c19early.org December 2025 Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Nicolini -32% 1.32 [0.85-2.06] death 151 (n) 177 (n) Improvement, RR [CI] Treatment Control Kim 87% 0.13 [0.02-0.68] death 2/14 14/28 Milic -150% 2.50 [1.58-3.94] death 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] death 479 (n) 1,824 (n) Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Late treatment -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk All studies -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk 4 darunavir COVID-19 serious outcomes c19early.org December 2025 Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Effect extraction pre-specified(most serious outcome) Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Early treatment -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk All studies -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk 1 darunavir COVID-19 viral clearance result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Early treatment -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk All studies -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk 1 darunavir COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Effect extraction pre-specified(most serious outcome) Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.64 Early treatment -22% 1.22 [0.53-2.78] 15 (n) 15 (n) 22% higher risk Nicolini -32% 1.32 [0.85-2.06] death 151 (n) 177 (n) Improvement, RR [CI] Treatment Control Kim 87% 0.13 [0.02-0.68] death 2/14 14/28 Milic -150% 2.50 [1.58-3.94] death 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] death 479 (n) 1,824 (n) Tau​2​ = 0.25, I​2​ = 84.1%, p = 0.32 Late treatment -34% 1.34 [0.76-2.38] 2/759 14/2,187 34% higher risk All studies -34% 1.34 [0.82-2.20] 2/774 14/2,202 34% higher risk 5 darunavir COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.22, I​2​ = 79.7%, p = 0.24 Effect extraction pre-specified(most serious outcome) Favors darunavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Chen (RCT) -22% 1.22 [0.53-2.78] viral+ 15 (n) 15 (n) Improvement, RR [CI] Treatment Control Nicolini -32% 1.32 [0.85-2.06] death 151 (n) 177 (n) Kim 87% 0.13 [0.02-0.68] death 2/14 14/28 Milic -150% 2.50 [1.58-3.94] death 115 (n) 158 (n) Milic -48% 1.48 [1.04-2.11] death/int. 115 (n) 158 (n) CORIST Di Castelnuovo -89% 1.89 [1.53-2.34] death 479 (n) 1,824 (n) Darunavir COVID-19 outcomes c19early.org December 2025 Favors darunavir Favors control